INCY Incyte Corporation
Company Analysis
Latest News
🟢 INCY is trading 4% up today as investors buy into its strong earnings and pipeline story
INCY is trading 4% up at $108.59 as investors continue to buy into its strong recent earnings and pipeline story despite concerns about a 2028 patent cliff. •...
Incyte Rallies Past $109 on Lingering Earnings Glow — But Can It Outrun the 2028 Patent Cliff?
Shares of Incyte Corporation climbed 4.4% in pre-market trading to $109.00 on June 24, extending a weeklong rebound from below $99 as investors continue to...
🟢 INCY is trading 4.4% up today on multiple positive catalysts including a Truist Securities price target raise
• Incyte is trading 4.4% up at $109.00 today, buoyed by several positive company-specific announcements. • Truist Securities raised its price target to $105.00...
🟢 INCY trading 4.4% up today, fueled by strong Q1 earnings and recent CMS settlement
INCY is trading at $109.00 (up 4.4%) in pre-market, continuing its rebound from last week's selloff. • The company reported a strong Q1 2026 earnings beat on...
🟢 INCY extends move to 5.2% up
INCY is trading at $103.28, up 5.2% versus the comparison close of $98.22 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Incyte Corporation is trading 4.1% up today after a favorable CMS settlement over Opzelura Medicaid rebates
Incyte Corporation is trading 4.1% up today at $102.25 after announcing a favorable litigation settlement with the Centers for Medicare & Medicaid Services...
Incyte Reaches Favorable CMS Settlement for Opzelura, Expects $246M Benefit
Incyte Corporation announced it has reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve litigation over Medicaid rebate...
Incyte Wins Japan Approval for Minjuvi, Targeting Aggressive Lymphoma
Japan’s Ministry of Health, Labour and Welfare approved Incyte’s drug Minjuvi (tafasitamab). The approval authorizes Minjuvi for use in combination with...
Incyte and Mirum’s Bone Disease Drug Cuts Lesions 81%, Wins Priority Review
Incyte and Mirum Pharmaceuticals announced positive results from a pivotal Phase 2 study of zilurgisertib. The drug targets Fibrodysplasia Ossificans...
🔴 Incyte Corporation extends move to 5.0% down
INCY is trading at $103.09, down 5.0% versus the comparison close of $108.53 during regular trading. This is a price-movement alert; no separate...
🔴 Incyte Corporation is trading 4.03% down today on apparent profit-taking despite a strong broader market
Incyte Corporation is trading 4.03% down today at $104.16 on apparent profit-taking as the move lacks a clear company-specific catalyst. • The sharp intraday...
Incyte reports positive tafasitamab results, cutting lymphoma progression risk by 25%
Incyte announced positive results from its pivotal Phase 3 frontMIND trial for tafasitamab. The study tested tafasitamab in combination with lenalidomide and...
🟢 Incyte Corporation is trading 5.8% up today following positive growth commentary and valuation-focused research updates
Incyte Corporation is trading 5.8% up at $109.20 following positive growth commentary and valuation-focused research updates highlighting strong 2025 results...
🟢 Incyte Corporation is trading 5.08% up
INCY is trading at $108.47, up 5.08%.
🟢 Incyte Corporation is trading 4.1% up today as investors cheer the company's largest-ever acquisition
Incyte Corporation is trading 4.1% up at $107.43 as the stock continues to rally following a major strategic move. • On June 8, 2026, Incyte announced its...
Incyte Shareholders Approve All Proposals at 2026 Annual Meeting
Incyte Corporation announced the results of its Annual Meeting of Shareholders held on June 8, 2026, where stockholders approved all proposals, including the...
🔴 Incyte Corporation is trading 4.4% down today after announcing a $2 billion acquisition of Vega Therapeutics
Incyte Corporation is trading 4.4% down at $96.22 after announcing a major acquisition of Vega Therapeutics for up to $2.0 billion, including $1.25 billion...
Incyte to Acquire Vega Therapeutics for up to $2.0 Billion, Expanding Hematology Portfolio
Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, for an upfront payment of $1.25...
Incyte Nears $2 Billion Star Therapeutics Deal, Targeting Bleeding Disorder Drug
Incyte is reportedly nearing a $2 billion acquisition of privately held Star Therapeutics. The agreement includes a $1.25 billion upfront cash payment....
🟢 Incyte Corporation is trading 4.4% up today as it extends a three-day rebound
Incyte Corporation is trading 4.4% up at $105.72 on momentum and dip-buying as the stock extends a three-day recovery from levels below $93. • The move...